Wed, 16 October 2019
Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio and Adverum Biotechnologies hope to change how a we treat a common cause of vision loss in seniors, and why United Healthcare's latest quarterly results sent shares soaring.
Check out more of our content here:
Direct download: 20191016_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT